Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Cashman, Vancouver
Joanne Cashman, Vancouver CA
| Patent application number | Description | Published |
|---|---|---|
| 20090192082 | CXCR4 ANTAGONIST TREATMENT OF HEMATOPOIETIC CELLS - Compositions comprising a peptide consisting of an amino acid sequence derived from a P2G-substituted SDF-1 protein are taught. The amino acid sequence consists of a first sequence consisting of 8 to 17 amino acids from the N-terminal portion of the SDF-1 protein and having a conserved KGVS motif. The amino acid sequences may also consist of one or more optional components selected from the group consisting of a second sequence consisting of 8 to 17 amino acids from the N-terminal portion of the SDF-1 protein and having a conserved KGVS motif, wherein the second sequence is covalently joined to the first sequence with or without a linker; and, a third sequence consisting of LKWIQEYLEKALN, or conservative substitutions thereof, wherein the third sequence is covalently joined to the first sequence with the linker. Methods of increasing multiplication of hematopoietic cells and enhancing proliferation of hematopoietic cells during engraftment are also taught. | 07-30-2009 |
| 20110118193 | TREATMENT OF LIQUID CANCERS - A use of a composition comprising an SDF-1 peptide having the sequence KGVSLSYR is taught. The composition can be used in the manufacture of a medicament for the treatment of a blood cancer in a mammal by administering the medicament in a therapeutically effective amount. | 05-19-2011 |
Johanne Cashman, Vancouver CA
| Patent application number | Description | Published |
|---|---|---|
| 20110104295 | PHARMACEUTICAL COMPOSITIONS AND METHODS RELATING TO INHIBITING FIBROUS ADHESIONS OR INFLAMMATORY DISEASE USING LOW SULPHATE FUCANS - Compositions and methods involving administration of agents useful for the treatment, prevention, inhibition, etc., of inflammatory disease or fibrous adhesions using low sulphate fucans and, if desired, one or more other anti-inflammatory disease or anti-fibrous adhesion agent. | 05-05-2011 |
Johanne Diane Cashman, Vancouver CA
Neil Cashman, Vancouver CA
| Patent application number | Description | Published |
|---|---|---|
| 20090098151 | ALS-SPECIFIC PEPTIDE COMPOSITION - The invention relates to a composition for eliciting an immune response in an animal to produce an antibody that binds selectively to an amyotrophic lateral sclerosis (ALS)-specific epitope. | 04-16-2009 |
| 20090280125 | Prion epitopes and methods of use thereof - Prion peptides comprising prion epitopes and fusions thereof, that display enhanced immunogenicity are described. Also described are methods of treating and diagnosing prion disease. | 11-12-2009 |
| 20110124018 | DETECTION OF PATHOGENIC POLYPEPTIDES USING AN EPITOPE PROTECTION ASSAY - The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. | 05-26-2011 |
| 20110135673 | EPITOPE PROTECTION ASSAY - The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof. | 06-09-2011 |
Neil R. Cashman, Vancouver CA
| Patent application number | Description | Published |
|---|---|---|
| 20080206251 | Methods and Compositions to Treat and Detect Misfolded-SOD1 Mediated Diseases - The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis and macular degeneration, glaucoma, ischemia, cerebral infarction, myocardial infarction, atherosclerosis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease or necrotizing enterocolitis using disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1. In addition, the invention includes methods of diagnosing Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis in a subject. Also, the invention provides methods of identifying substances for the treatment or prevention of Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis and kits using the binding proteins of the invention. | 08-28-2008 |
| 20100233176 | METHODS AND SYSTEMS FOR PREDICTING MISFOLDED PROTEIN EPITOPES - A method and system to identify an epitope unique to a misfolded form of a protein is provided. Sets of one or more amino acid residues are selected from a model representing the structure of the protein; the free energy of unfolding of each set is determined; and the epitope is identified from the sets having a total probability of unfolding above a minimum probability or a free energy of unfolding below a minimum energy. In other aspects, the invention provides for the use of epitopes identified by the epitope prediction methods, and related antibodies, to diagnose and treat disease and to screen samples for the presence of such epitopes. | 09-16-2010 |
| 20110020358 | Methods and Compositions for Detecting Amyotrophic Lateral Sclerosis - The invention provides binding proteins that bind to misfolded or monomeric SOD1, and not to native homodimeric SOD1. The invention also includes methods of diagnosing, detecting or monitoring amyotrophic lateral sclerosis in a subject. In addition, the invention provides methods of identifying substances for the treatment or prevention of amyotrophic lateral sclerosis and kits using the binding proteins of the invention. | 01-27-2011 |
| 20110125478 | METHODS AND SYSTEMS FOR DETERMINING LOCALIZED DIELECTRIC PROPERTIES OF A MOLECULE - The present disclosure describes methods, systems and techniques for determining a localized dielectric property of a molecule. A molecular model of at least a portion of the molecule is obtained. The molecular model is partitioned into cavities, and for each of the cavities, the permittivity within the cavity is iteratively determined based on permittivity outside of the cavity and electronic and nuclear polarizability within the cavity. Beneficially, this allows for different permittivities to be determined for different portions of the molecule, and is advantageous over simply assigning a single permittivity to the entire molecule. | 05-26-2011 |
Neil Roy Cashman, Vancouver CA
| Patent application number | Description | Published |
|---|---|---|
| 20090175884 | MISFOLDED PROTEINS IN CANCER TREATMENT AND DIAGNOSIS - Cancer cells are identified and inhibited using agents that bind to epitopes unique to misfolded forms of surface proteins presented by the cancer cells. In one embodiment, cancer cells are identified and treated using antibodies that bind to a YYX epitope available on the misfolded form of the prion protein, PrP, which has been identified on various cancer cell lineages. | 07-09-2009 |